Market Overview

J.P. Morgan Reiterates Overweight Rating on Gilead Sciences

Related GILD
Markets Mostly Higher As Earnings Season Continues To Impress
Statement from FDA Confirms Approval of Gilead's Zydelig
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

In a report published Wednesday, J.P. Morgan & Co. reiterated its Overweight rating on Gilead Sciences (NASDAQ: GILD).

J.P. Morgan noted, “This morning, Gilead announced the acquisition of YM Biosciences for approximately $510M ($2.95/share) in cash. The transaction has been unanimously approved by YM's board and is expected to close in 1Q13. YM's lead assed is CYT387, a janus kinase inhibitor (JAK), being developed for myelofibrosis (positive phase 1-2 data). Overall, the transaction makes sense to us given Gilead's recent strategy of expanding into hematology/oncology. Indeed, CYT387 will complement Gilead's current hematology/oncology pipeline which currently includes idelalisib (GS-1101) in phase 3 (CLL/iNHL) and simtuzumab (GS-6624) in phase 2 testing (myelofibrosis, colorectal cancer, pancreatic and certain fibrotic disease). Gilead intends to initiate a phase 3 trial of CYT387 in myelofibrosis in 2H13. We are encouraged by the expanding hematology/oncology pipeline which provides additional shots on goal, beyond the core anti-viral franchise. We reiterate our Overweight rating largely based on a strong core HIV business and a significant opportunity in hep-C, as well as the optionally beyond the anti-viral franchises.”

Gilead Sciences closed on Tuesday at $76.34.

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (GILD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free